Explore our thought leadership series from the Economist Intelligence Unit on topics such as cardiac risk stratification, pandemic testing strategies, traumatic brain injury and more. Discover how recent innovations driven by clinical diagnostics will advance patient care across the healthcare ecosystem. Corresponding infographics provide high-level snapshots of each report’s content.
Learn about the benefits of effective testing strategies in the report and infographic.
Learn about the new evidence and opportunities for improving CVD risk stratification.
Learn about the current evidence and advancements for evaluation and management of traumatic brain injury.
Find out which countries are on the forefront of using a multianalyte approach and understand their use in three case studies.
Learn why the clinical laboratory must be integrated into the wider health system for healthcare organizations to achieve their full benefits.
Learn why innovative and targeted diagnostic testing is key to improving health outcomes for women.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Learn how Abbott has helped physicians evaluate suspected mild traumatic brain injury (mTBI).
Discover how Alinity uses technology to redefine and improve operational productivity and confidence in your laboratory.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
